Ambrx Biopharma (AMAM) announced that the Company will be added to the NASDAQ Biotechnology Index (NBI), effective prior to the market open on Monday, December 18, 2023.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMAM:
- Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
- Ambrx Biopharma provides update on APEX-01
- Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Ambrx Biopharma price target lowered to $22 from $26 at Baird